•
Dec 31, 2023

Quest Diagnostics Q4 2023 Earnings Report

Quest Diagnostics' Q4 2023 financial performance reflected a decrease in revenue compared to the previous year, but an increase in earnings per share.

Key Takeaways

Quest Diagnostics reported a slight decrease in Q4 revenue by 1.9% year-over-year, totaling $2.29 billion. However, the company saw a significant increase in reported diluted EPS, up 95.4% to $1.70, and an adjusted diluted EPS increase of 8.6% to $2.15. The base business revenues increased by 4.7% to $2.25 billion, while COVID-19 testing revenues decreased by 79.8% to $37 million.

Q4 revenues decreased by 1.9% to $2.29 billion.

Reported diluted EPS increased by 95.4% to $1.70.

Adjusted diluted EPS increased by 8.6% to $2.15.

Base business revenues increased by 4.7% to $2.25 billion.

Total Revenue
$2.29B
Previous year: $2.33B
-1.9%
EPS
$2.15
Previous year: $1.98
+8.6%
Revenue per requisition
-3.5%
Previous year: -5.1%
-31.4%
Requisition volume
1.9%
Previous year: -11.2%
-117.0%
Organic requisition volume
1.4%
Previous year: -11.4%
-112.3%
Gross Profit
$740M
Previous year: $758M
-2.4%
Cash and Equivalents
$686M
Previous year: $315M
+117.8%
Free Cash Flow
$455M
Previous year: $187M
+143.3%
Total Assets
$14B
Previous year: $12.8B
+9.2%

Quest Diagnostics

Quest Diagnostics

Quest Diagnostics Revenue by Segment

Forward Guidance

Quest Diagnostics expects full year 2024 reported diluted EPS to be between $7.69 and $7.99, and adjusted diluted EPS to be between $8.60 and $8.90. They estimate net revenues between $9.35 billion and $9.45 billion. Cash provided by operations is expected to be approximately $1.3 billion, and capital expenditures approximately $420 million.

Positive Outlook

  • Net revenues are expected to increase between 1.1% and 2.1%.
  • Reported diluted EPS is expected to be between $7.69 and $7.99.
  • Adjusted diluted EPS is expected to be between $8.60 and $8.90.
  • Cash provided by operations is expected to be approximately $1.3 billion.
  • The company has raised its dividend annually since 2011.